| ASSET | QUARTER | % RETURN |
|---|---|---|
Aspen Aerogels (ASPN) | Q2 2019 | 180.71% |
Red Cat (RCAT) | Q2 2019 | 169.23% |
Chimerix (CMRX) | Q2 2019 | 105.71% |
Avadel Pharmaceuticals (AVDL) | Q2 2019 | 100.69% |
Red Violet (RDVT) | Q2 2019 | 85.35% |
Atomera (ATOM) | Q2 2019 | 81.59% |
Kodiak Sciences (KOD) | Q2 2019 | 79.17% |
Adient (ADNT) | Q2 2019 | 78.06% |
Cantaloupe (CTLP) | Q2 2019 | 77.75% |
Syndax Pharmaceuticals (SNDX) | Q2 2019 | 75% |
Harrow Health (HROW) | Q2 2019 | 73.65% |
EverQuote Inc Class A (EVER) | Q2 2019 | 69.93% |
Alphatec (ATEC) | Q2 2019 | 68.77% |
SolarEdge Technologies (SEDG) | Q2 2019 | 63.51% |
Opera (OPRA) | Q2 2019 | 59.39% |
DRDGOLD Limited ADR (DRD) | Q2 2019 | 55.61% |
MeiraGTx (MGTX) | Q2 2019 | 53.69% |
Safehold (SAFE) | Q2 2019 | 51.47% |
V2X (VVX) | Q2 2019 | 51.4% |
PROS (PRO) | Q2 2019 | 50.73% |
Lifeway Foods (LWAY) | Q2 2019 | 49.79% |
National Research (NRC) | Q2 2019 | 49.72% |
P10 (PX) | Q2 2019 | 48.42% |
Arvinas (ARVN) | Q2 2019 | 47.58% |
Endava (DAVA) | Q2 2019 | 46.33% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
